Edmond M Kwan1,2, Chao Dai3, Heidi Fettke1, Christine Hauser4, Maria M Docanto1, Patricia Bukczynska4, Nicole Ng4,5,6, Siavash Foroughi5,6, Lisa-Jane K Graham7, Kate Mahon7,8,9, Winston Tan10, Xiaohong Wang3, Zhixin Zhao3, Tiantian Zheng3, Kemin Zhou3, Jianjun Yu3, Pan Du3, Lisa G Horvath7,8,9,11, Shidong Jia3, Manish Kohli12, Arun A Azad1,13,14. 1. Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia. 2. Department of Medical Oncology, Monash Health, Melbourne, Australia. 3. Predicine Inc, Hayward, CA. 4. Peter MacCallum Cancer Centre, Melbourne, Australia. 5. Personalized Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. 6. Department of Medical Biology, The University of Melbourne, Melbourne, Australia. 7. Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia. 8. University of Sydney, Sydney, Australia. 9. Garvan Institute of Medical Research, Sydney, Australia. 10. Division of Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL. 11. Royal Prince Alfred Hospital, Sydney, Australia. 12. Division of Medical Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 13. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. 14. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Abstract
Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition in PTEN-deficient mCRPC, we profiled PTEN-PI3K-AKT pathway aberrations in patients with mCRPC using a novel cfDNA assay optimized for CNV detection. METHODS: A next-generation sequencing-based cfDNA assay was used to profile 231 patients with mCRPC from two independent cohorts (Australian, n = 78; United States, n = 153). PTEN-PI3K-AKT pathway genomic aberrations were correlated with clinical outcomes, including progression-free survival and overall survival (OS). RESULTS: PTEN loss and PIK3CA gain were detected in 37% (85 of 231) and 17% (39 of 231) of patients, respectively. Poorer outcomes were observed in patients with PTEN-PI3K-AKT pathway aberrations, including those with dual PTEN loss and PIK3CA gain (hazard ratio 2.3, 95% CI 1.2 to 4.4). Cumulative CNV burden in the PTEN-PI3K-AKT and androgen receptor (AR) pathways was associated with significantly worse clinical outcomes (0 v 1 v ≥ 2 CNVs in Australian cohort: median OS 33.5 v 17.2 v 9.7 months, P < .001; 0 v 1 v ≥ 2 CNVs in US cohort: median OS 35.5 v 14.3 v 9.2 months, P < .001). Notably, 21% (31 of 146) of PTEN-neutral patients harbored alternative PTEN-PI3K-AKT pathway aberrations. CONCLUSION: PTEN-PI3K-AKT pathway CNVs were readily detected using our cfDNA assay, with the prevalence of PTEN loss comparable with tissue-based studies. Additional PTEN-PI3K-AKT pathway aberrations were found in one fifth of PTEN-neutral cases. Concurrent CNVs in the PTEN-PI3K-AKT and AR pathways portended poor survival, and identifying this high-risk patient subset for dual AR/Akt inhibition may optimize precision treatment with Akt inhibitors in mCRPC.
Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition in PTEN-deficient mCRPC, we profiled PTEN-PI3K-AKT pathway aberrations in patients with mCRPC using a novel cfDNA assay optimized for CNV detection. METHODS: A next-generation sequencing-based cfDNA assay was used to profile 231 patients with mCRPC from two independent cohorts (Australian, n = 78; United States, n = 153). PTEN-PI3K-AKT pathway genomic aberrations were correlated with clinical outcomes, including progression-free survival and overall survival (OS). RESULTS: PTEN loss and PIK3CA gain were detected in 37% (85 of 231) and 17% (39 of 231) of patients, respectively. Poorer outcomes were observed in patients with PTEN-PI3K-AKT pathway aberrations, including those with dual PTEN loss and PIK3CA gain (hazard ratio 2.3, 95% CI 1.2 to 4.4). Cumulative CNV burden in the PTEN-PI3K-AKT and androgen receptor (AR) pathways was associated with significantly worse clinical outcomes (0 v 1 v ≥ 2 CNVs in Australian cohort: median OS 33.5 v 17.2 v 9.7 months, P < .001; 0 v 1 v ≥ 2 CNVs in US cohort: median OS 35.5 v 14.3 v 9.2 months, P < .001). Notably, 21% (31 of 146) of PTEN-neutral patients harbored alternative PTEN-PI3K-AKT pathway aberrations. CONCLUSION: PTEN-PI3K-AKT pathway CNVs were readily detected using our cfDNA assay, with the prevalence of PTEN loss comparable with tissue-based studies. Additional PTEN-PI3K-AKT pathway aberrations were found in one fifth of PTEN-neutral cases. Concurrent CNVs in the PTEN-PI3K-AKT and AR pathways portended poor survival, and identifying this high-risk patient subset for dual AR/Akt inhibition may optimize precision treatment with Akt inhibitors in mCRPC.
Authors: Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins Journal: Nature Date: 2012-07-12 Impact factor: 49.962
Authors: Manish Kohli; Jian Li; Meijun Du; David W Hillman; Scott M Dehm; Winston Tan; Rachel Carlson; Michael B Campion; Liguo Wang; Liewei Wang; Huijuan Zhang; Peng Zhang; Deepak Kilari; Chiang-Ching Huang; Liang Wang Journal: Prostate Cancer Prostatic Dis Date: 2018-06-01 Impact factor: 5.554
Authors: Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova Journal: Nat Med Date: 2009-04-12 Impact factor: 53.440
Authors: David A Quigley; Ha X Dang; Shuang G Zhao; Paul Lloyd; Rahul Aggarwal; Joshi J Alumkal; Adam Foye; Vishal Kothari; Marc D Perry; Adina M Bailey; Denise Playdle; Travis J Barnard; Li Zhang; Jin Zhang; Jack F Youngren; Marcin P Cieslik; Abhijit Parolia; Tomasz M Beer; George Thomas; Kim N Chi; Martin Gleave; Nathan A Lack; Amina Zoubeidi; Robert E Reiter; Matthew B Rettig; Owen Witte; Charles J Ryan; Lawrence Fong; Won Kim; Terence Friedlander; Jonathan Chou; Haolong Li; Rajdeep Das; Hui Li; Ruhollah Moussavi-Baygi; Hani Goodarzi; Luke A Gilbert; Primo N Lara; Christopher P Evans; Theodore C Goldstein; Joshua M Stuart; Scott A Tomlins; Daniel E Spratt; R Keira Cheetham; Donavan T Cheng; Kyle Farh; Julian S Gehring; Jörg Hakenberg; Arnold Liao; Philip G Febbo; John Shon; Brad Sickler; Serafim Batzoglou; Karen E Knudsen; Housheng H He; Jiaoti Huang; Alexander W Wyatt; Scott M Dehm; Alan Ashworth; Arul M Chinnaiyan; Christopher A Maher; Eric J Small; Felix Y Feng Journal: Cell Date: 2018-07-19 Impact factor: 41.582
Authors: Alexander W Wyatt; Arun A Azad; Stanislav V Volik; Matti Annala; Kevin Beja; Brian McConeghy; Anne Haegert; Evan W Warner; Fan Mo; Sonal Brahmbhatt; Robert Shukin; Stephane Le Bihan; Martin E Gleave; Matti Nykter; Colin C Collins; Kim N Chi Journal: JAMA Oncol Date: 2016-12-01 Impact factor: 31.777
Authors: Kevin Chen; Misty D Shields; Pradeep S Chauhan; Ricardo J Ramirez; Peter K Harris; Melissa A Reimers; Jose P Zevallos; Andrew A Davis; Bruna Pellini; Aadel A Chaudhuri Journal: Mol Diagn Ther Date: 2021-11-01 Impact factor: 4.476
Authors: Umang Swami; Raquel Mae Zimmerman; Roberto H Nussenzveig; Edgar Javier Hernandez; Yeonjung Jo; Nicolas Sayegh; Sergiusz Wesolowski; Lesli A Kiedrowski; Pedro C Barata; Gordon Howard Lemmon; Mehmet A Bilen; Elisabeth I Heath; Lakshminarayan Nandagopal; Hani M Babiker; Sumanta K Pal; Michael Lilly; Benjamin L Maughan; Benjamin Haaland; Mark Yandell; Oliver Sartor; Neeraj Agarwal Journal: Front Oncol Date: 2022-09-15 Impact factor: 5.738
Authors: Blossom Mak; Hui-Ming Lin; Edmond M Kwan; Heidi Fettke; Ben Tran; Ian D Davis; Kate Mahon; Martin R Stockler; Karen Briscoe; Gavin Marx; Alison Zhang; Megan Crumbaker; Winston Tan; Kevin Huynh; Thomas G Meikle; Natalie A Mellett; Andrew J Hoy; Pan Du; Jianjun Yu; Shidong Jia; Anthony M Joshua; David J Waugh; Lisa M Butler; Manish Kohli; Peter J Meikle; Arun A Azad; Lisa G Horvath Journal: BMC Med Date: 2022-03-25 Impact factor: 8.775